MA56397A - Protéines de liaison à l'il1rap - Google Patents

Protéines de liaison à l'il1rap

Info

Publication number
MA56397A
MA56397A MA056397A MA56397A MA56397A MA 56397 A MA56397 A MA 56397A MA 056397 A MA056397 A MA 056397A MA 56397 A MA56397 A MA 56397A MA 56397 A MA56397 A MA 56397A
Authority
MA
Morocco
Prior art keywords
binding proteins
il1rap binding
il1rap
proteins
binding
Prior art date
Application number
MA056397A
Other languages
English (en)
Inventor
John G Emery
Qi Fei
Shiyong Gong
Sanjay Kumar
Fang Ren
Teddy Yang
Hua Ying
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA56397A publication Critical patent/MA56397A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA056397A 2019-06-26 2020-06-22 Protéines de liaison à l'il1rap MA56397A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019093114 2019-06-26

Publications (1)

Publication Number Publication Date
MA56397A true MA56397A (fr) 2022-05-04

Family

ID=71738216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056397A MA56397A (fr) 2019-06-26 2020-06-22 Protéines de liaison à l'il1rap

Country Status (12)

Country Link
US (1) US20230295313A1 (fr)
EP (1) EP3990494A1 (fr)
JP (1) JP2022539178A (fr)
KR (1) KR20220026585A (fr)
CN (1) CN114222760A (fr)
AU (1) AU2020308053A1 (fr)
BR (1) BR112021025476A2 (fr)
CA (1) CA3143211A1 (fr)
IL (1) IL289145A (fr)
MA (1) MA56397A (fr)
MX (1) MX2021015651A (fr)
WO (1) WO2020261097A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062836A (zh) * 2021-02-05 2023-11-14 勃林格殷格翰国际有限公司 抗il1rap抗体
EP4341290A1 (fr) 2021-05-21 2024-03-27 LEO Pharma A/S Anticorps de protéine accessoire de récepteur anti-il-1
CN116574189A (zh) * 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP2275541B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité d'une molécule fonctionnelle immunologiquement
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP3214175A1 (fr) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Anticorps ctla-4 humains et leurs utilisations
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1606446A (zh) 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
KR100850393B1 (ko) 2000-06-30 2008-08-04 글락소 그룹 리미티드 퀴나졸린 화합물의 제조방법
WO2002012258A1 (fr) 2000-08-04 2002-02-14 Corixa Corporation Nouveaux composes immuno-effecteurs
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP1525223B1 (fr) 2002-06-13 2007-11-21 Crucell Holland B.V. Molecules de liaison agonistes au recepteur ox40 (=cd134) humain et utilisation therapeutique
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
JP4997108B2 (ja) 2005-07-22 2012-08-08 協和発酵キリン株式会社 遺伝子組換え抗体組成物
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
JP5761997B2 (ja) 2007-12-14 2015-08-12 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｏｘ４０受容体に対する結合分子
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2486058A1 (fr) * 2009-10-09 2012-08-15 Sanofi Polypeptides de liaison au « récepteur de produits terminaux de glycation avancée » ainsi que compositions et procédés les mettant en jeu
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
ES2630328T3 (es) 2010-08-23 2017-08-21 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
CA2824719C (fr) 2011-01-19 2020-06-02 Cantargia Ab Anticorps anti-il1rap et leur utilisation dans le traitement de tumeurs solides
CA2845810C (fr) 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procedes d'utilisation
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
KR102200274B1 (ko) * 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
EP3313887A2 (fr) * 2015-06-26 2018-05-02 MAB Discovery GmbH Anticorps monoclonaux anti-il-1racp
MX2018005545A (es) * 2015-11-02 2019-02-20 Janssen Pharmaceutica Nv Anticuerpos anti-il1rap, moleculas de union a antigenos biespecificas que se unen a il1rap y cd3, y usos de estas.
WO2018071910A2 (fr) * 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anticorps anti-il1-rap

Also Published As

Publication number Publication date
EP3990494A1 (fr) 2022-05-04
WO2020261097A1 (fr) 2020-12-30
KR20220026585A (ko) 2022-03-04
IL289145A (en) 2022-02-01
MX2021015651A (es) 2022-06-14
JP2022539178A (ja) 2022-09-07
CN114222760A (zh) 2022-03-22
BR112021025476A2 (pt) 2022-10-11
US20230295313A1 (en) 2023-09-21
CA3143211A1 (fr) 2020-12-30
AU2020308053A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
MA50942A (fr) Protéines de liaison à l'adn modifiées
MA54513A (fr) Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
MA50613A (fr) Molécules de liaison spécifique à l'hpv
MA49270A (fr) Récepteurs de liaison à l'antigène améliorés
MA43576A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA56397A (fr) Protéines de liaison à l'il1rap
MA52182A (fr) Molécules de liaison à l'antigène ciblant her2 comprenant 4-1bbl
IL272064A (en) Binding proteins 1
MA41414A (fr) Protéines de liaison agonistes d' icos
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
MA43816A (fr) Protéines de liaison inductibles et méthodes d'utilisation
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
UA42295S (uk) Комп'ютер
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l'adn
UA42369S (uk) Комп'ютер
MA46844A (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation
DK3737402T5 (da) Modificeret protein
GB201818576D0 (en) Arginase 2 polypeptides
IL304317A (en) tgf–beta–rii binding proteins
GB201919294D0 (en) Antibodies or binding proteins
MA55010A (fr) Système d'électrodes
MA52175A (fr) Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène